STOCK TITAN

Zoetis to Participate in the Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2022. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET.

Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more information, visit www.zoetis.com.

ZTS-COR
ZTS-IR

Media Contacts:

Bill Price

1-973-443-2742 (o)

william.price@zoetis.com

Kristen Seely

1-973-443-2777 (o)

kristen.seely@zoetis.com

Investor Contact:

Steve Frank

1-973-822-7141 (o)

steve.frank@zoetis.com

Source: Zoetis Inc.

ZOETIS INC.

NYSE:ZTS

ZTS Rankings

ZTS Latest News

ZTS Stock Data

72.43B
456.86M
0.23%
95.6%
0.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PARSIPPANY

About ZTS

Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.